C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies for serious diseases, including cancer and rare disorders. Utilizing its proprietary Controlled Covalent Catalysis (C4) platform, the company designs small molecules that selectively bind to and induce the degradation of disease-causing proteins, aiming to create innovative treatments with improved efficacy and safety profiles.
Company News
C4 Therapeutics saw a significant stock price increase of over 34% after Stephens analyst Sudan Loganathan upgraded the stock to overweight, citing promising pipeline progress and potential in multiple myeloma drug market.
C4 Therapeutics reported positive data for its multiple myeloma drug candidate cemsidomide, with a 50% overall response rate at the highest dose level. The company is prioritizing the development of cemsidomide and plans to seek partnership opportunities for its BRAF program.
C4 Therapeutics (NASDAQ:CCCC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indiffere...
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -1.49% and 37.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?